Risk factor
Considerable default risk
Profitability factor
Very favourable analyst view
About
Based in South Korea, i-SENS, Inc. specializes in the provision of diagnostic biosensor technology. Its product portfolio encompasses a range of point-of-care (POC) testing equipment, including analyzers for HbA1c, blood gas, electrolytes, and PT/INR. Additionally, the company supplies the CareSens line of blood glucose monitors, along with lancing and various complementary medical devices, and offers diabetes management services. The firm's solutions are distributed internationally, reaching approximately 110 nations, notably across the United States, Japan, and European markets. Established in 2000, i-SENS, Inc. maintains its corporate headquarters in Seoul, South Korea.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITD.